College of Animal Science and Technology, Northwest A&F University, Yangling 712100, Shaanxi, China.
Pneumology and Pulmonary Cell Research, Department of Biomedicine, University of Basel and University Hospital Basel, CH-4031 Basel, Switzerland; and.
J Immunol. 2019 Jan 1;202(1):37-47. doi: 10.4049/jimmunol.1800782. Epub 2018 Dec 10.
Tissue remodeling of subepithelial mesenchymal cells is a major pathologic condition of chronic obstructive pulmonary disease and asthma. Fibroblasts contribute to fibrotic events and inflammation in both airway diseases. Recent mechanistic studies established a link between mitochondrial dysfunction or aberrant biogenesis leading to tissue remodeling of the airway wall in asthma. Protein arginine methyltransferase-1 (PRMT1) participated in airway wall remodeling in pulmonary inflammation. This study investigated the mechanism by which PRMT1 regulates mitochondrial mass in primary human airway wall fibroblasts. Fibroblasts from control or asthma patients were stimulated with TGF-β for up to 48 h, and the signaling pathways controlling PRMT1 expression and mitochondrial mass were analyzed. PRMT1 activity was suppressed by the pan-PRMT inhibitor AMI-1. The SMAD2/3 pathway was blocked by SB203580 and C/EBPβ by small interference RNA treatment. The data obtained from unstimulated cells showed a significantly higher basal expression of PRMT1 and mitochondrial markers in asthmatic compared with control fibroblasts. In all cells, TGF-β significantly increased the expression of PRMT1 through SMAD2/3 and C/EBPβ. Subsequently, PRMT1 upregulated the expression of the mitochondria regulators PGC-1α and heat shock protein 60. Both the inhibition of the SAMD2/3 pathway or PRMT1 attenuated TGF-β-induced mitochondrial mass and C/EBPβ and α-SMA expression. These findings suggest that the signaling sequence controlling mitochondria in primary human lung fibroblasts is as follows: TGF-β→SMAD2/3→C/EBPβ→PRMT1→PGC-1α. Therefore, PRMT1 and C/EBPβ present a novel therapeutic and diagnostic target for airway wall remodeling in chronic lung diseases.
细胞外基质重塑是慢性阻塞性肺疾病和哮喘的主要病理状态。成纤维细胞参与这两种气道疾病的纤维化事件和炎症。最近的机制研究表明,线粒体功能障碍或异常生物发生与哮喘气道壁的组织重塑之间存在联系。精氨酸甲基转移酶-1(PRMT1)参与了肺部炎症中的气道壁重塑。本研究探讨了 PRMT1 调节原代人气道壁成纤维细胞中线粒体质量的机制。用 TGF-β 刺激对照或哮喘患者的成纤维细胞长达 48 小时,分析控制 PRMT1 表达和线粒体质量的信号通路。用泛 PRMT 抑制剂 AMI-1 抑制 PRMT1 活性。用 SB203580 阻断 SMAD2/3 途径,用小干扰 RNA 处理阻断 C/EBPβ。未刺激细胞获得的数据显示,与对照成纤维细胞相比,哮喘患者的 PRMT1 和线粒体标志物的基础表达明显更高。在所有细胞中,TGF-β 通过 SMAD2/3 和 C/EBPβ 显著增加 PRMT1 的表达。随后,PRMT1 上调了线粒体调节因子 PGC-1α 和热休克蛋白 60 的表达。SMAD2/3 途径或 PRMT1 的抑制均可减弱 TGF-β 诱导的线粒体质量和 C/EBPβ 和 α-SMA 表达。这些发现表明,控制原代人肺成纤维细胞中线粒体的信号序列如下:TGF-β→SMAD2/3→C/EBPβ→PRMT1→PGC-1α。因此,PRMT1 和 C/EBPβ 为慢性肺部疾病的气道壁重塑提供了一个新的治疗和诊断靶点。